Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI scan could spot liver cancer earlier in High-Risk patients

NCT ID NCT06658782

Diagnosis Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether a 20-minute MRI scan without dye can detect liver cancer earlier than the usual ultrasound in 300 people with cirrhosis who are at high risk. Participants will get both scans every 6 months for 30 months. The goal is to see if the MRI catches cancers that ultrasound might miss, while being safer and cheaper than contrast scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
non-contrast magnetic resonance imaging (MRI) scan
What this could lead to
If successful, this could offer a safer, more accurate way to spot liver cancer early in people with cirrhosis, potentially saving more lives.
What could go wrong
This is a feasibility study with only 300 participants. The MRI may not prove better than ultrasound in practice, and results may not apply to all groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Apr 2039

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with a high risk of HCC will be included. Participants will have liver cirrhosis from Alcohol related liver disease, metabolic dysfunction associated steatotic liver disease, chronic hepatitis C, chronic hepatitis B or genetic haemochromatosis, or with chronic liver disease and prior successful treatment for HCC without recurrence and who are back in surveillance with USS.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Participant is willing and able to give informed consent for participation in the study AND * All genders, aged 18 years or above AND * Eligible for HCC US surveillance in the opinion of the local investigators AND * Child Pugh score A or B AND * Diagnosed with liver cirrhosis due to ArLD, MASLD, chronic hepatitis C, chronic hepatitis B, genetic haemochromatosis AND * Have an annual risk of HCC of at least 3% as determined by the aMAP score OR * Participants with chronic liver disease (with or without cirrhosis) who had successful treatment for HCC, have not had a recurrence and have returned to 6 monthly surveillance with USS Exclusion Criteria: * • Contraindication to MRI * Known allergy / reaction to intravenous gadolinium contrast * Prisoners * Pregnancy or breast feeding * Previous liver transplant * Participants who are known to have indeterminate liver nodules on prior imaging requiring ongoing follow-up with MRI or CT * Previous HCC treated with curative intent and still being followed up with CT or MRI with contrast for possible recurrence * Estimated glomerular filtration rate of \<30 ml/min/1.73m2 * Participant is on haemodialysis * Participants who are unlikely to comply with the study procedures in the opinion of the local investigator * In the view of the clinician, if the participant has a co-morbidity likely to lead to death within the following 12 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis hepatitis C induced liver cirrhosis hepatocellular carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis Cirrhosis and chronic liver disease Cirrhosis due to hepatitis B Cirrhosis due to hepatitis C Cirrhosis of the liver Hepatocellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bournemouth University Hospital

    RECRUITING

    Bournemouth, United Kingdom

  • Oxford University Hospitals NHS Foundation Trudt

    RECRUITING

    Oxford, Oxon, ox3 9du, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.